Overview of Geralgine Plus (Acetaminophen,Codeine)

Property	Description
Active ingredients	Acetaminophen, Codeine
Form	Oral (Tablet, Capsule, Solution)
Pharmacological class	Analgesic (Opioid-containing), Antipyretic
Common use	Relief of mild to moderate pain and fever
Origin	Synthetic and Semi-synthetic derived

What type of medicine is Geralgine Plus (Acetaminophen, Codeine)?

Geralgine Plus is a prescription-only combination medicine primarily categorized as an opioid-containing analgesic and antipyretic (fever reducer). It is a fixed-dose preparation, containing two active substances to offer greater relief than either ingredient alone. The combination is pharmacologically classified as an analgesic because it blends a centrally acting component (codeine) with a peripherally acting component (acetaminophen). Clinically, this combination is recognized for its ability to provide relief when milder, non-opioid options are inadequate. Acetaminophen with codeine is included in the analgesic ladder for the management of pain.

What are the Active Ingredients in Geralgine Plus?

Geralgine Plus is composed of the active ingredients Acetaminophen (a non-opioid pain reliever) and Codeine (a semi-synthetic opioid analgesic). This dual composition allows the medicine to target discomfort through multiple mechanisms simultaneously. Codeine is an opioid that is often used in combination with non-opioid analgesics for pain relief. This combination formula differentiates it from basic over-the-counter single-ingredient products like plain acetaminophen. The medicine is commonly provided in various oral dosage forms, such as tablets or capsules, intended for the oral route of administration.

What is the General Purpose of Geralgine Plus?

The general purpose of Geralgine Plus is to provide enhanced relief for pain, such as discomfort following dental procedures or minor injuries, and to reduce fever, particularly when standard non-opioid medications are not sufficient. The dual composition is effective because Codeine changes how the central nervous system processes pain, while Acetaminophen works to inhibit the pain-causing chemicals. Combining these two mechanisms results in a multi-level intervention for moderate discomfort, supported by decades of pharmacological studies.

Regulatory References

What side effects are possible with Geralgine Plus (Acetaminophen,Codeine)?

Possible Side Effects and Safety Information

The medicine's safety profile is officially characterized by adverse reactions categorized by frequency and the body system affected, based on regulatory documentation from authorities such as the FDA and EMA. This profile highlights both common and serious potential risks.

Adverse Reaction Categories

Classification Pattern	Examples of Adverse Reactions
Common Effects	Nausea, vomiting, constipation, dizziness, and somnolence (drowsiness) are frequently reported, typically affecting the gastrointestinal and nervous systems.
Rare Effects	Rare documented effects include various skin reactions (e.g., rash, pruritus) and specific blood disorders (blood dyscrasias).

Serious Adverse Reactions

Regulatory documents include high-level safety warnings regarding certain critical risks. The most significant concern associated with the acetaminophen component is the potential for acute liver failure/hepatotoxicity, particularly with cumulative high doses. For the codeine component, a documented serious risk is respiratory depression, which can be life-threatening. Other serious reactions include severe cutaneous adverse reactions (SCARs) and anaphylaxis.

Population and Exposure-Related Safety Notes

Official labeling defines specific constraints for certain patient groups. The use of this combination is generally restricted for pediatric patients (e.g., post-tonsillectomy/adenoidectomy) and is contraindicated for nursing mothers due to the risk of infant harm from codeine metabolites. The risk of developing drug tolerance and dependence is officially associated with the long-term exposure to the opioid component. Furthermore, the official label warns of the potential for profound sedation when used with other CNS depressants.

Overdose and Emergency Response

Overdose and when to seek help

Suspected overdose of Geralgine Plus must be treated as an immediate medical emergency due to the distinct toxic profiles of its two active components. Regulatory authorities mandate that immediate medical attention be sought for any suspected overexposure, even if the person appears asymptomatic.

Documented Overdose Manifestations and Severe Outcomes

The official profile describes two primary toxic risks:

Acetaminophen Toxicity: Early symptoms may include nausea, vomiting, diaphoresis (sweating), and general malaise. The critical severe outcome is potentially fatal hepatic necrosis (liver failure) and metabolic acidosis, which may present as a delayed effect.
Codeine Toxicity: Manifestations are linked to central nervous system (CNS) depression, including somnolence, stupor, miosis (pinpoint pupils), and critically, life-threatening respiratory depression leading to respiratory arrest and circulatory collapse.

Emergency Actions and Management

Immediate help-seeking is required. The official management approach is defined by component-specific antidotes. N-acetylcysteine (NAC) is the specific regulatory-listed antidote for the acetaminophen component. Naloxone is the specific opioid antagonist used to reverse the respiratory depression caused by codeine. Supportive care and continuous hospital monitoring of hepatic function and respiratory status are required following overexposure. The regulatory labeling notes that accidental ingestion of even a single dose, especially by children, constitutes a risk for fatal overdose.

Therapeutic Uses of Geralgine Plus (Acetaminophen,Codeine)

What Geralgine Plus (Acetaminophen, Codeine) Treats: Main Uses and Benefits

The primary role of Geralgine Plus may be part of symptomatic management in situations where patients experience discomfort that requires additional support, primarily in acute, short-term settings. The combination is used to help relieve pain and is classified as both an analgesic and an antipyretic.

This medication is commonly used across conditions presenting with acute episodes, where symptoms related to physical discomfort, such as musculoskeletal aches, dental discomfort, or generalized pain, may create noticeable physiological strain. The combination is relevant for easing the overall symptom load, particularly when symptoms related to systemic imbalance or inflammatory states also produce an elevated body temperature.

It is commonly applied in clinical settings that involve acute or unstable symptom patterns, such as following minor surgical interventions, common dental procedures, or discomfort sustained from acute injuries. This use is relevant when short-term symptomatic assistance is needed, which may help improve day-to-day comfort during symptomatic periods. The medication helps address symptom clusters that may become intense or disruptive during acute episodes.

Quick Fact: Relief for Mild to Moderate Pain

Regulatory References

NIH MedlinePlus overview of Acetaminophen and Codeine

Eligibility and Restrictions for Use

Who Can and Cannot Use Geralgine Plus (Acetaminophen, Codeine)?

The eligibility for Geralgine Plus is strictly defined by regulatory bodies based on age, physiological status, and underlying health conditions to mitigate serious risks associated with the codeine component.

Absolute Contraindications

The medicine is prohibited for use in the following populations:

Children younger than 12 years of age.
Adolescents younger than 18 years of age who have undergone tonsillectomy and/or adenoidectomy.
Women who are breastfeeding (due to the risk of serious adverse reactions in the infant).
Patients known to be CYP2D6 ultra-rapid metabolizers of codeine.
Individuals with a known hypersensitivity to codeine, acetaminophen, or any component.
Patients with significant respiratory depression, acute severe bronchial asthma, or known gastrointestinal obstruction.

Restricted or Conditional Use

Use is strongly restricted or requires caution in several groups:

Adults: The medicine is approved for adults when non-opioid options are insufficient for pain relief.
Adolescents (12–18 years): Use should be avoided if they have conditions that compromise breathing, such as obstructive sleep apnea or severe lung disease.
Organ Impairment: Patients with severe hepatic or renal impairment require caution and often a reduced dose, as accumulation can increase risk.
Pregnancy: Prolonged use during pregnancy is discouraged due to the risk of Neonatal Opioid Withdrawal Syndrome (NOWS) in the newborn.
Elderly: Use requires caution and close monitoring due to potential age-related decline in organ function.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interactions with Geralgine Plus are defined by the properties of its two active ingredients: Codeine (an opioid) and Acetaminophen. The most significant risks involve additive Central Nervous System (CNS) effects and potential liver toxicity.

Critical Interaction Categories

Interaction Type	Interacting Medicines/Classes	Interaction Mechanism & Risk
CNS Depressants	Alcohol, Benzodiazepines, other Opioids, Sedatives, Muscle Relaxants, General Anesthetics, certain Antihistamines.	Combining these can lead to additive CNS depression, causing profound sedation, severe respiratory depression, coma, and death. Reserve concomitant use only when alternative options are inadequate.
Hepatotoxic Agents	Other Acetaminophen-containing products.	Concomitant use increases the total daily intake of acetaminophen, which carries a risk of acute liver failure, sometimes resulting in transplant or death. Do not exceed the prescribed daily limit.
CYP450 Enzyme Modulators	Strong CYP2D6 Inhibitors (e.g., certain antidepressants), CYP3A4 Inhibitors, and CYP3A4 Inducers (e.g., certain antivirals, antifungals).	These drugs can alter Codeine's metabolism to its active metabolite, morphine. This may result in reduced analgesic effect (with inhibitors) or increased toxicity (with certain enzyme changes).
Serotonergic Drugs	Certain Antidepressants (SSRIs, SNRIs), certain Migraine Medications (triptans).	Concomitant use can cause Serotonin Syndrome, a potentially life-threatening condition.
MAO Inhibitors (MAOIs)	Isocarboxazid, Linezolid, Phenelzine, Selegiline, Tranylcypromine, Methylene Blue.	The use of this product is contraindicated within 14 days of taking any MAOI due to risk of serious adverse reactions.
Anticoagulants	Warfarin.	The acetaminophen component may increase the anticoagulant effect of warfarin, requiring close monitoring.
Opioid Antagonists	Naltrexone, Samidorphan, Mixed Agonists (e.g., Pentazocine).	These medications can reduce the product's pain-relieving effects or precipitate opioid withdrawal symptoms.

Procedural Constraint

Do not consume alcoholic beverages while taking this medication. Patients must report all concurrent medicines, vitamins, nutritional supplements, and herbal products, such as St. John's wort or Tryptophan.

Mechanism of Action

Acetaminophen primarily exerts its effects within the central nervous system (CNS), acting as a reversible inhibitor of cyclooxygenase (COX) enzymes, specifically COX-2 and a putative COX-3 isoform. This enzymatic inhibition decreases the biosynthesis of prostaglandins (PGs) from arachidonic acid. Reduced PG concentration in the CNS leads to a modulated response in thermoregulatory and signaling pathways. Codeine, a prodrug, undergoes O-demethylation primarily by the cytochrome P450 2D6 (CYP2D6) enzyme to form its active metabolite, morphine. Morphine functions as an agonist at mu-opioid receptors (MORs), which are G-protein coupled receptors (GPCRs) localized extensively throughout the CNS, including the brainstem, spinal cord, and thalamus. MOR activation inhibits adenylyl cyclase, reducing intracellular cyclic AMP (cAMP) levels. This cellular consequence leads to the opening of G protein-coupled inwardly rectifying potassium (GIRK) channels, resulting in hyperpolarization of the neuronal membrane, and the inhibition of voltage-gated calcium channels, decreasing neurotransmitter release from the presynaptic terminal. The system-level physiological consequence of combined mu-opioid receptor agonism and CNS prostaglandin modulation is an altered perception and transmission of afferent signals.

Dosage and Administration Information

Geralgine Plus is administered via the oral route, available in forms such as tablets, capsules, and oral solutions. The use of this combination product is for acute, short-term pain relief, and adherence to the principle of using the lowest effective dose for the shortest possible duration is indicated.

Administration Entity	Official Dosing Guideline
Standard Single Dose	Ranges from 30 mg to 60 mg of Codeine combined with 300 mg to 1,000 mg of Acetaminophen.
Dosing Interval	Minimum of 4 to 6 hours between administrations, to be taken as needed for pain.
Maximum Daily Limit	4,000 mg total Acetaminophen and 360 mg total Codeine from all sources.

The medication can be taken with or without food, as its absorption profile is not significantly affected. When using the oral solution, precise dosing requires measurement with a calibrated medical device rather than a household spoon. Furthermore, tablets must be swallowed whole and not crushed, cut, or dissolved, to preserve the integrity of the dosage form.

Specific constraints apply for certain groups. Use is contraindicated in children younger than 12 years of age. For older adults and patients with impaired kidney or liver function, cautious dose selection is necessary, often requiring lower doses or extended dosing intervals.

Recent Clinical Evidence

Research evidence / Overview of studies for Geralgine Plus (Acetaminophen,Codeine)

Evidence for Use in Acute, Short-Term Pain Relief

Clinical research has explored its use in conditions associated with acute, short-term physical discomfort. Studies exploring this area rely primarily on Randomized Controlled Trials (RCTs), a common design in clinical research, and comprehensive systematic reviews. This research was applied in studies examining patient-reported outcomes related to discomfort following events such as dental extractions or minor surgical procedures. Researchers monitored short-term symptom patterns in populations consisting mostly of adults.

The systematic reviews and meta-analyses describe patterns observed in the studies over brief, defined time intervals. The trials examined differences in patient-reported outcomes between participants who received the combination and those who received an inactive substance (placebo).

Despite the body of research, certainty remains low regarding certain aspects. Evidence highlights that the results apply only to the populations studied and that the outcome patterns of the codeine component are associated with individual genetic differences in how individuals metabolize the drug. Furthermore, comparative evidence is lacking regarding whether adding a low dose of codeine research examined incremental changes compared to the acetaminophen component used alone.

Evidence for Use in Mild to Moderate Cancer Pain

The combination was studied in research scenarios related to cancer pain, particularly for discomfort categorized as mild to moderate. The research base includes systematic reviews that summarize the available Randomized Controlled Trials (RCTs). Studies monitored outcomes related to patient-reported physical discomfort and overall perceived change.

Research so far describes patterns in outcomes related to physical discomfort over short follow-up durations. Findings help contextualize how patients reported their experience during the study period. However, the evidence is limited in this context. Reports indicate that the sample sizes were modest in many of the relevant trials, and follow-up durations were often short-term, lasting only days to a few weeks. There is limited information for long-term outcomes.

What is Still Uncertain About the Research

The research landscape is characterized by existing findings and areas of uncertainty. Long-term effects are not fully established, as research exploring maintenance data or durability of response is lacking. Furthermore, certainty remains low regarding the research outcomes of the combination in addressing certain types of pain, such as chronic neuropathic pain, because systematic reviews were unable to identify adequate, high-quality trials to evaluate this use.

Frequently Asked Questions (FAQ)

Common questions about Geralgine Plus (Acetaminophen,Codeine) (FAQ)

Q: How long can the pain relief from Geralgine Plus be expected to last?

A: According to official product information, the pain-relieving effect of the codeine component typically reaches its peak concentration within two hours of administration. Generally, the analgesic effect is expected to persist between four and six hours.

Q: What is the expected experience of taking Geralgine Plus for the first time?

A: The official Medication Guide indicates that common effects may include feeling dizzy, lightheaded, or sleepy. The label suggests that individuals should understand how the medicine affects them before engaging in activities that require mental alertness, such as driving or operating heavy machinery.

Q: Why does Geralgine Plus often cause constipation?

A: Regulatory documents state that the codeine component can cause constipation by slowing down the movement of material through the colon. This action is due to the way codeine affects the muscle contractions, or propulsive waves, in the digestive tract.

Q: Can Geralgine Plus be taken with other over-the-counter pain relievers?

A: Official product information explicitly requires individuals to avoid taking Geralgine Plus with any other product that contains acetaminophen. The decision to combine it with other pain relievers, such as nonsteroidal anti-inflammatory drugs (NSAIDs), is based on a discussion with a healthcare professional regarding potential risks and interactions.

Q: What signs of a serious problem should make me stop taking Geralgine Plus immediately?

A: Official regulatory documents describe that severe reactions require prompt attention. These signs include symptoms such as slow or shallow breathing, a fast heartbeat, chest pain, or swelling of the face, tongue, or throat.

Q: What is an 'ultra-rapid metabolizer' of codeine and why does it matter?

A: An ultra-rapid metabolizer has a genetic variation that allows the body to convert codeine into its active ingredient, morphine, more rapidly and completely than normal. According to official warnings, this difference can lead to higher than expected levels of morphine in the body, which carries a risk of severe respiratory depression or signs of overdose.

Q: Does Geralgine Plus make it unsafe to drive or operate machinery?

A: Official safety information indicates that activities like driving or operating heavy machinery should be avoided until an individual understands how the medication affects them. This is because the medicine can cause sleepiness, dizziness, or lightheadedness, affecting mental and physical alertness.

Q: Are there different strengths of Geralgine Plus, and how does that affect risk?

A: Official product labels confirm that this combination product is available in different strengths, containing varying amounts of codeine and acetaminophen. The risk of toxicity, overdose, and developing dependence is related to the specific dosage and the total amount of active ingredients consumed.

Q: Is it important to tell all my healthcare providers that I am taking Geralgine Plus?

A: The official Medication Guide specifies that individuals should inform their doctor and pharmacist about all other prescription medications, nonprescription medicines, vitamins, nutritional supplements, and herbal products being used. This is necessary to help prevent drug interactions and ensure safe use.

Q: Is stomach pain a normal side effect or a sign of a serious issue?

A: Official product information lists abdominal pain as a possible side effect. While it can occur, official guidance indicates that contact with a healthcare provider is appropriate if this symptom becomes severe or worrisome.

Q: What happens if I forget to take a dose of Geralgine Plus?

A: According to the Medication Guide, when a dose is missed, individuals typically resume the dosing schedule by taking the next dose only when needed and as directed by their prescribing professional. This medicine should only be taken as prescribed.

Q: Can Geralgine Plus affect a person's fertility or hormones?

A: Official regulatory documents indicate that chronic use of opioids may affect the body’s hormone system, specifically the hypothalamic-pituitary-gonadal axis. This can potentially lead to a condition known as androgen deficiency, which has been associated with effects such as low libido, impotence, or infertility.

Q: What is the meaning of the 'Boxed Warning' on Geralgine Plus packaging?

A: The Boxed Warning, or 'Black Box Warning', is the strongest warning required by the FDA on product labeling. Official documents state this warning highlights the most serious safety risks, including the potential for addiction and misuse, life-threatening respiratory depression, and severe liver damage (hepatotoxicity).

Q: Why do some people with a family history of substance abuse need extra caution with Geralgine Plus?

A: Official product labeling states that individuals with a personal or family history of substance abuse (involving drugs or alcohol) or mental illness are categorized as being at an increased risk. This is due to the potential for addiction, abuse, or misuse associated with the opioid component of the medicine.

Q: Is it important to monitor for low blood pressure while taking Geralgine Plus?

A: Regulatory documents indicate that the codeine component can cause peripheral vasodilation, which is the widening of blood vessels. This effect may result in orthostatic hypotension, which is a drop in blood pressure that occurs when standing up, and may cause dizziness or fainting.

Q: Can taking Geralgine Plus cause or increase the risk of seizures?

A: Official warnings state that the medication may cause seizures. Official warnings specify that patients with a current or previous history of seizures should inform their healthcare provider.

Q: What is the purpose of the Medication Guide (MedGuide) that comes with the prescription?

A: The FDA requires a Medication Guide (MedGuide) to be dispensed with this medicine as part of the Risk Evaluation and Mitigation Strategy (REMS). The MedGuide's purpose is to ensure patients receive critical information about the safe use, potential serious risks, proper storage, and appropriate disposal of this opioid-containing product.

Q: Can long-term use of Geralgine Plus lead to a lower sex drive?

A: Official regulatory documents state that chronic use of opioids may lead to androgen deficiency, a hormonal imbalance. One way this condition can manifest is through low libido (decreased sexual desire) or erectile dysfunction.

How should Geralgine Plus (Acetaminophen,Codeine) be stored and disposed of?

This product contains a Schedule III controlled substance (Codeine), requiring specific storage and disposal to prevent theft, abuse, or accidental exposure, especially by children.

Storage Requirements

Safe Place: Store the medication securely in the container it came in, tightly closed, in a location that is out of sight and reach of children and pets. This helps protect the tablets from theft or misuse.
Temperature: Store at room temperature, away from excess heat and moisture (e.g., not in the bathroom).

Disposal Instructions

Preferred Method: The best option is to use a drug take-back program, such as a DEA-authorized collector or a mail-back envelope.
Alternative: If a take-back program is not readily available, mix the tablets with an undesirable substance (like used coffee grounds or dirt), place the mixture in a sealable bag or container, and discard it in the household trash. Scratch out personal information on the prescription label before disposing of the empty packaging.

Geralgine Plus (Acetaminophen,Codeine)